Unlock instant, AI-driven research and patent intelligence for your innovation.

Tumor necrosis factor antagonists and their use in endometriosis

A technology of endometriosis and antagonists, applied in cytokine/lymphokine/interferon receptors, anti-cytokine/lymphokine/interferon immunoglobulin, medical preparations containing active ingredients, etc. Able to resolve issues where no prompts were given, immunological abnormalities, etc.

Inactive Publication Date: 2005-07-27
MERCK SERONO SA
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these studies, like others performed on various models involving endometriosis, have no real in vivo effects on TNF and TNF-RI, whether membrane-bound or not, during the development of endometriotic lesions. or soluble, neither is given any indication, only the immunological abnormalities associated with endometriosis are described

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor necrosis factor antagonists and their use in endometriosis
  • Tumor necrosis factor antagonists and their use in endometriosis
  • Tumor necrosis factor antagonists and their use in endometriosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0050] Materials and methods

[0051] Animals: Female Sprague-Dawley rats (250-275 g) were purchased from Charles River, Italy (Calco, Lecco, Italy). Animals were raised in the following environment: temperature 22±2°C, relative humidity 55±10%, ventilation by HEPA99.997% filter at 15±3 times per hour, using 12 hours in a 24-hour cycle (7:00- 19:00) with artificial lighting. The animals were acclimatized in this environment for at least one week before the experiment. Animals were fed ad libitum diet with standard pelleted chow.

[0052] Research drug: anti-ovulation peptide is prepared and provided by Bachem (California, U.S.), and the human recombinant soluble TNF-RI molecule used in the examples has a sequence equivalent to human TNF-RI fragment 20-180 (Nophar et al., 1990), in was produced in CHO cells and supplied under the name r-hTBP-1 by Interpharm Laboratories Ltd. (Israel).

[0053] Materials: General cell culture materials were purchased from Gibco BRL, Life Tec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Tumor necrosis factor antagonists are administered in therapeutically effective doses to treat and / or prevent endometriosis. The antagonists of this invention typically are selected from among several classes but preferably are soluble TNF receptors. The antagonists are useful for the regression of endometriotic lesions and, if combined with other active ingredients, for amelioration of related disorders, like infertility.

Description

field of invention [0001] Administration of a therapeutically effective amount of a tumor necrosis factor antagonist treats and / or prevents endometriosis. Antagonists of the invention are generally selected among a variety of molecules. However, soluble TNF receptors are preferred. Such antagonists are useful for regression of endometriotic lesions. If used in combination with other active ingredients, related diseases such as infertility can be improved. Background of the invention [0002] Endometriosis is a disease of the female reproductive system characterized by the presence of endometrial glands and extracavitary matrix of the endometrium and the muscular system of the uterus. The most commonly affected anatomical sites are the ovaries, uterosacral ligaments, peritoneum of the pelvis, rectovaginal septum, cervix, vagina, fallopian tubes, and vulva. In general, endometriosis seems to infiltrate the underlying tissue deeply from the rectovaginal septum and cannot be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K38/00A61K38/17A61K39/395A61P15/00A61P15/08C07K14/715C07K16/24
CPCC07K16/241A61K38/1793A61K2039/505C07K2319/30A61P15/00A61P15/08A61K38/17
Inventor F·博雷利列M·德安东尼奥F·马尔泰利
Owner MERCK SERONO SA